CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Prothena Corporation PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Prothena Corporation PLC
77 Sir John Rogersons Quay
Block C, Grand Canal Docklands
Phone: +353 12362500p:+353 12362500 DUBLIN, D02 T804  Ireland Ticker: PRTAPRTA
Business Summary
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Lars G.Ekman 74 12/1/2012 12/1/2012
President, Chief Executive Officer, Director Gene G.Kinney 55 9/30/2016 12/1/2012
Chief Financial Officer, Chief Strategy Officer Tran B.Nguyen 50 9/1/2021 3/1/2013
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Prothena Biosciences Inc 650 Gateway Boulevard, Suite 100 South San Francisco CA United States

Business Names
Business Name
Othair Prothena Limited
Prothena Pharma Limited
Prothena Platform Technologies Limited
PRTA

General Information
Number of Employees: 173 (As of 12/31/2023)
Outstanding Shares: 53,808,732 (As of 9/30/2024)
Shareholders: 5,221
Stock Exchange: NASD
Federal Tax Id: 431256213
Fax Number: +353 19023510


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024